Talha Badar: Quick overview on Ph-like Acute Lymphoblastic Leukemia
Talha Badar, Hematology/Oncology specialist at Mayo Clinic, shared a post on X:
“Quick overview on Ph-like Acute Lymphoblastic Leukemia.
Salient features:
1. Incidence: 25-30% among adults with ALL, higher in Hispanics.
2. Gene-expression profile similar to that of Ph+positive ALL but lack BCR::ABL1.
3. CRLF2+ more common (older age and high WBC) and associated with poorer outcomes.
4. Associated with poor outcomes in adults, long term survival is in the range of 20-25% (compared to around 80-90% in children).
5. JAKi combination for Ph like ALL with JAK stat pathway alterations and Dasatinib for ABL class alterations, are being evaluated in clinical trials.
6. Response to conventional chemotherapy and immunotherapy has been inferior in this sub-group of patients.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023